Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Surya Pharmaceuticals has shut down two active pharmaceutical ingredients (API) manufacturing plants in Jammu and Panchkula, India.
Subscribe to our email newsletter
The move follows the company’s rising debt burdens, which has amounted to a total of Rs15bn ($290m).
The company said that the Jammu plant is still under trial for production and has been shut down for now, reports moneycontrol.com.
Surya Pharmaceuticals focuses on contract manufacturing, custom synthesis, FTE research, and marketing of pharmaceuticals products and services to clients across the globe.
The company’s product portfolio includes a range of APIs, fine intermediates, finished drug formulations (FDFs) and phyto pharmaceuticals.